Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Takeda gets license to Hutchmed cancer compound

by Gina Vitale
January 29, 2023 | A version of this story appeared in Volume 101, Issue 4

The structure of fruquintinib.

Takeda Pharmaceutical has entered an agreement with HutchMed to license the Chinese pharmaceutical firm’s tyrosine kinase inhibitor fruquintinib. Takeda will pay $400 million up front and up to $730 million in further potential payments. Fruquintinib is intended to treat refractory metastatic colorectal cancer, and the companies say the deal bolsters Takeda’s oncology portfolio. Takeda will get an exclusive worldwide license other than in China, Hong Kong, and Macau for the development and commercialization of the drug.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.